Giovannini-Green ZEM, Gamble J-M, Barrett B, Gao Z, Stuckless S, Parfrey PS. Canadian Pharmacists Journal. Variation and appropriateness of antipsychotic use in long-term care facilities across Newfoundland and Labrador [Internet]. 2021;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85104822147&partnerID=MN8TOARS

Amegadzie JE, Gorgui J, Acheampong L, Gamble J-M, Farrell J, Gao Z. Journal of Asthma. Comparative safety and effectiveness of inhaled bronchodilators and corticosteroids for treating asthma–COPD overlap: a systematic review and meta-analysis [Internet]. 2021;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85075145584&partnerID=MN8TOARS

Pelletier R, Ng K, Alkabbani W, Labib Y, Mourad N, Gamble J-M. Therapeutic Advances in Drug Safety. Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews [Internet]. 2021;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85099858370&partnerID=MN8TOARS

Alkabbani W, Gamble JM, Eurich DT, Minhas-Sandu J, Shah BR, Alsabbagh W, et al. Risk of hospitalization and death associated with Sodium Glucose Cotransporter-2 inhibitors: A comparison with five other classes of antidiabetic drugs. Diabetes and Metabolism. 2021;

Grightmire B, Alkabbani W, Gamble J-M. American Journal of Medicine Open. Peak performance: Putting type 1 diabetes management recommendations for athletes to the test [Internet]. 2022;Available from: https://doi.org/10.1016/j.ajmo.2022.100011

Alkabbani W, Zongo A, Minhas-Sandhu JK, Eurich DT, Shah BR, Alsabbagh MW, et al. Canadian Journal of Diabetes. Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score–matched Population-based Cohort Study [Internet]. 2022;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85129507933&partnerID=MN8TOARS

N. Ing SBong, Amoud R, Gamble J-M, Alsabbagh MW. Canadian Journal of Diabetes. Trends and Determinants of Self-reported Aspirin Use Among Patients With Diabetes Stratified by Presence and Risk of Cardiovascular Diseases: A Repeated Pan-Canadian Cross-sectional Study [Internet]. 2022;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85129977549&partnerID=MN8TOARS

Alkabbani W, Gamble J-M, Eurich DT, Minhas-Sandhu JK, Shah BR, Alsabbagh MW, et al. Diabetes and Metabolism. Risk of hospitalization and death associated with sodium glucose cotransporter-2 inhibitors: A comparison with five other classes of antidiabetic drugs [Internet]. 2022;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85120915534&partnerID=MN8TOARS

Alkabbani W, Zongo A, Minhas-Sandhu JK, Eurich DT, Shah BR, Alsabbagh MW, et al. Diabetic Medicine. Five comparative cohorts to assess the risk of genital tract infections associated with sodium-glucose cotransporter-2 inhibitors initiation in type 2 diabetes mellitus [Internet]. 2022;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85129462097&partnerID=MN8TOARS

Alkabbani W, Pelletier R, Beazely MA, Labib Y, Quan B, Gamble J-M. Drug Safety. Drug–Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data [Internet]. 2022;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85125655701&partnerID=MN8TOARS

Gamble J-M, Alkabbani W. Drug Safety. Authors’ Reply to Noguchi’s comment on: “Drug-Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data.” [Internet]. 2022;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85132201172&partnerID=MN8TOARS

Amegadzie JE, Gamble J-M, Farrell J, Gao Z. International Journal of COPD. Association between Inhaled β₂-agonists Initiation and Risk of Major Adverse Cardiovascular Events: A Population-based Nested Case-Control Study [Internet]. 2022;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85131104214&partnerID=MN8TOARS

Amegadzie JE, Gamble J-M, Farrell J, Gao Z. Respiratory Research. Risk of all-cause mortality or hospitalization for pneumonia associated with inhaled β2-agonists in patients with asthma, COPD or asthma-COPD overlap [Internet]. 2022;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85144299296&partnerID=MN8TOARS

Amegadzie JEmil, Gamble J-M, Farrell J, Gao Z. Association between Inhaled beta(2)-agonists Initiation and Risk of Major Adverse Cardiovascular Events: A Population-based Nested Case-Control Study. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. 2022;17:1205-1217.

Gamble J-M, Alkabbani W. Authors' Reply to Noguchi's comment on: ``Drug-Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data''. DRUG SAFETY. 2022;45:813-814.

Alkabbani W, Pelletier R, Beazely MA, Labib Y, Quan B, Gamble J-M. Drug-Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data. DRUG SAFETY. 2022;45:287-295.

Alkabbani W, Zongo A, Minhas-Sandhu JK, Eurich DT, Shah BR, Alsabbagh MWasem, et al. Five comparative cohorts to assess the risk of genital tract infections associated with sodium-glucose cotransporter-2 inhibitors initiation in type 2 diabetes mellitus. DIABETIC MEDICINE. 2022;39:e14858.

Alkabbani W, Gamble J-M, Eurich DT, Minhas-Sandhu JK, Shah BR, Alsabbagh MWasem, et al. Risk of hospitalization and death associated with sodium glucose cotransporter-2 inhibitors: A comparison with five other classes of antidiabetic drugs. DIABETES & METABOLISM. 2022;48:101305.

Pelletier R, Nagge J, Gamble J-M. Variation in bleeding risk estimates among online calculators Cross-sectional study of apps used by and for patients with atrial fibrillation. CANADIAN FAMILY PHYSICIAN. 2022;68:E127-E135.

Alkabbani W, Gamble J-M. British Journal of Clinical Pharmacology. Active-comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 inhibitors [Internet]. 2023;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85124712639&partnerID=MN8TOARS